Searched for
L ORAL INDIA
Delhi Gymkhana Club served show cause notice in eviction proceedings; asked to explain why it should not be evicted by July 7The Union Government has escalated eviction proceedings against the Delhi Gymkhana Club, issuing a show cause notice under the Public Premi...- Honasa Consumer to acquire majority stake in Fluence Pharma at Rs 135-crore valuationHonasa Consumer has secured a majority stake in Mumbai's hair therapy brand Fluence Pharma for Rs 135 crore. This move marks the company's ...
- Children’s ibuprofen recalled in 2026: Nearly 90,000 bottles of pain-relieving medication pulled nationwideChildren's ibuprofen recalled: A major recall impacts nearly 90,000 bottles of children's ibuprofen oral suspension. The medication, manufa...
- Mercury soars, and so do sales of rehydration drinks in IndiaIndia is experiencing a surge in demand for dehydration-preventing drinks due to the intense heatwave. Electral sales have jumped 27% in Ma...
- Dabur becomes 2nd largest player in oral care in Modern Trade channels: CEODabur has become the second-largest player in the oral care segment in modern trade channels, driven by growth in its Dabur Red Toothpaste ...
- Granules India gets USFDA nod for generic Glycopyrrolate oral solutionGranules Pharmaceuticals Inc, a subsidiary of Granules India, has received approval from the USFDA for a generic Glycopyrrolate oral soluti...
- From Black to Blonde: The growing popularity of hair colouring in IndiaYoung Indians are increasingly opting for fashion shades of hair colours such as deep wine, caramel brown, and beige, instead of traditiona...
- Pure play brands to drive India's $30 billion beauty and personal care market opportunity: ReportIn comparison, China's BPC will grow 7% while Indonesia's market will expand 8%. India, that will account for nearly 5% of the global growt...
- Bombay high court dismisses Dish TV promoter’s plea against YES BankDish TV promoters maintain that they were neither borrowers nor guarantors for any loans of YES Bank. Senior counsels Darius Khambata and J...
- Market movers: Why did Lupin jump 4% & OMCs take a big hit due to electionsPharma stocks have been in demand given the rapid rise in dollar, which boosts the prospects of the export oriented companies. And, at such...
- BPaL regimen can cut time for treatment of drug-resistant TBBPaL is a six-month, alloral, three-drug regimen that is used to treat people with highly drug-resistant forms of TB. It consists of the TB...
- Bharat Parenterals gets DCGI nod for favipiravir oral suspensionThe company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parente...
- Analytical, data-led coaching is need of the hour: myJen.ai co-foundersThe startup has created and designed three AI-based products including uSpeek and kWurd to enhance video, oral and written communication an...
- JPC on data bill summons Facebook for deposition on August 10The committee last sought stakeholder feedback in February and wrote to companies and institutions asking for a presentation, which will su...
- Blackstone buys Essel Propack for up to $460 million, to launch open offer at Rs 139/shareEssel Group is in the process to sell various assets, including road and solar portfolios.
- Biocon introduces advanced therapy to treat Hepatitis CBiotechnology major Biocon launches advanced novel therapy for the treatment of Hepatitis C at a fraction of the global cost.
- Cipla launches generic hepatitis C drug 'Hepcvir-L' in IndiaCipla has launched generic tablets used for treating of hepatitis C under the brand name 'Hepcvir-L' costing Rs 25,000 for a bottle of 28 t...
- BBC documentary on gangrape: Supreme Court no to lawyer on plea to restrain BCI, SCBASC refused to restrain two lawyers' bodies from taking any action against an advocate for allegedly making derogatory remarks against women...
- Aurobindo Pharma gets USFDA nod to sell antibiotic oral suspensionThe approval by the USFDA is for strengths of 100 mg/5 ml and 200 mg/5 ml and the product is ready for launch, Aurobindo Pharma said in a s...
- DRL's Aurigene ties up with US firm CurisCuris has agreed to make payments of up to $52.5 million per programme including $42.5 million for approval and commercial milestones,
Load More
